Phase IIa

Alderley Park, Cheshire, U.K., August 19, 2026 Infex Therapeutics will present new Phase IIa data for RESP-X (INFEX702) in...

Alderley Park, Cheshire, U.K., May 21, 2026 Infex Therapeutics announced positive Phase IIa clinical trial results for RESP-X (INFEX702)...

Nes-Ziona, Israel — Nov. 24, 2025 — Enlivex Therapeutics Ltd. announced positive six-month topline results from the Phase IIa...